In our real-world cohort, according to our synovial pathotype classification that replaced the CD3 and CD38 markers by CD31 and CD90, to give more priority to myeloid and stromal cells, RA patients could be stratified into different subgroups with different risk ratios of clinical outcomes, especially 1-year radiographic progression. This evidence concerns the gene CD38 and rheumatoid arthritis.